Personalizing Breast Cancer Care: Pharmacist Strategies for Optimizing Oral Therapy Outcomes

This activity was originally presented live at Asembia's AXS26 Summit in Las Vegas, Nevada

Program Description

The treatment paradigm for breast cancer is shifting rapidly toward a personalized, oral-first approach. This shift is driven by two major factors: precision and autonomy. The integration of genomic testing has allowed oncology treatment regimens to move past traditional chemotherapies and instead use highly specific oral targeted therapies dictated by the tumor's molecular signature. However, shifting the site of care introduces unique challenges in clinical stewardship. Unlike treatment administered in clinic, where adherence is supervised, real-world data show that adherence to oral targeted agents can drop to 40% due to adverse effects and financial toxicity. This session will provide a clear, evidence-based framework for the clinical implications of key predictive biomarkers for oral targeted therapy alignment in both the adjuvant and metastatic breast cancer settings. Beyond drug selection, this activity addresses the practical complexities of long-term breast cancer management. Attendees will gain actionable insights into class-specific adverse effect mitigation strategies, ranging from managing hyperglycemia associated with PI3K inhibitors to the hematologic profiles of CDK4/6 inhibitors. Faculty presenters will also outline the logistical hurdles of oral therapies for breast cancer, such as navigating prior authorizations, specialty pharmacy coordination, and financial toxicity, ensuring accessible care for patients. The program features expert-led patient case discussions to support oncology pharmacists in translating high-level clinical trial data into actionable interventions for patients with breast cancer receiving oral therapies.

Target audience: Specialty pharmacists
Type of Activity: Application
Release date: May 12, 2026
Expiration date: May 12, 2027
Learner level: Foundational, Intermediate
Time to complete activity: 1.5 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Apply knowledge of key biomarkers and genomic alterations across breast cancer subtypes to support personalized therapy selection and sequencing of oral targeted treatments.
• Integrate emerging clinical data on oral targeted therapies across HR+, HER2+, and BRCA-mutated breast cancers to support evidence-based treatment decisions.
• Identify common adverse events and adherence barriers associated with oral targeted therapies in breast cancer to support pharmacist-led strategies for monitoring, prevention, and management.
• Explore pharmacist-driven strategies to improve access, affordability, and care coordination for patients receiving oral targeted breast cancer therapies through specialty pharmacy services.

Accreditation

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 290-0000-26-125-H01-P. The activity is available for CE credit through May 12, 2027.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Brooke Looney, PharmD, CSP, has the following relevant financial relationships with ineligible companies to disclose:

Grant/Research Support: Takeda

Consultant: AstraZeneca, Johnson & Johnson

The following contributors have no relevant financial relationships with ineligible companies to disclose:

Faculty

Julia L. Ziegengeist, PharmD, BCOP

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Daphne Davis; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com

Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms